Drug-Coated Balloons Market Report 2026

Drug-Coated Balloons Market Overview

• Drug-Coated Balloons market size has reached to $1.24 billion in 2025 • Expected to grow to $2.55 billion in 2030 at a compound annual growth rate (CAGR) of 15.6% • Growth Driver: Surging Ambulatory Surgery Centers Propel Growth In The Drug-Coated Balloon Market • Market Trend: Innovations in Drug-Coated Balloon Technology • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Drug-Coated Balloons Market?

A drug-coated balloon (DCB) is a medical device used in the treatment of narrowed or blocked blood vessels, primarily in the field of interventional cardiology and interventional radiology. It is designed to deliver medication directly to the site of vascular disease while simultaneously performing angioplasty. The main types of products included in the drug-coated balloons include drug-coated balloons for peripheral artery disease, drug-coated balloons for coronary artery disease, and drug-coated balloons for other indications. Drug-coated balloons (DCBs) for peripheral artery disease refer to a type of medical device used in the treatment of peripheral artery disease (PAD). PAD is a condition characterized by the narrowing or blockage of blood vessels outside of the heart or in the lower extremities. Various drug types are included, such as paclitaxel and sirolimus, which are used by several end-users, including hospitals, cardiac catheterization labs, and ambulatory surgical centers.

What Is The Drug-Coated Balloons Market Growth Forecast?

The drug-coated balloons market size is expected to see rapid growth in the next few years. It will grow to $2.55 billion in 2030 at a compound annual growth rate (CAGR) of 15.6%. The growth in the forecast period can be attributed to increasing use of dcb therapies in coronary applications, rising adoption of next-generation coating technologies, expansion of catheter-based interventions, growing investments in vascular innovation, increasing preference for stent-free treatment options. Major trends in the forecast period include increasing adoption of sirolimus-coated balloons, rising use of dcbs in peripheral artery disease, growing preference for minimally invasive vascular treatments, expansion of advanced drug-coating technologies, enhanced focus on improved drug delivery efficiency.

Global Drug-Coated Balloons Market Segmentation

1) By Product: Drug-Coated Balloons For Peripheral Artery Disease, Drug-Coated Balloons For Coronary Artery Disease 2) By Drug Type: Paclitaxel, Sirolimus 3) By End User: Hospitals, Cardiac Catheterization Labs, Ambulatory Surgical Centers Subsegments: 1) By Drug-Coated Balloons For Peripheral Artery Disease: Paclitaxel-Coated Balloons, Sirolimus-Coated Balloons 2) By Drug-Coated Balloons For Coronary Artery Disease: Paclitaxel-Coated Balloons, Sirolimus-Coated Balloons

What Is The Driver Of The Drug-Coated Balloons Market?

The growing number of ambulatory surgery centers is expected to propel the growth of the drug-coated balloon market going forward. An Ambulatory Surgical Center (ASC) is a medical facility dedicated to performing surgical procedures that do not require an overnight stay in a hospital. Drug-coated balloons play an important role in ambulatory surgery centers (ASC) as they typically offer shorter procedure times than those with standard balloons, leading to enhanced patient throughput and lower operational costs in ASCs. For instance, in March 2025, according to the Medicare Payment Advisory Commission (an independent U.S. federal advisory agency), from 2022 through 2023 the number of Medicare-certified ASCs rose 2.5% to 6,308 ASCs, reflecting a net increase of 155 facilities during 2023. Therefore, the growing number of ambulatory surgery centers is driving the growth of the drug-coated balloon industry.

Key Players In The Global Drug-Coated Balloons Market

Major companies operating in the drug-coated balloons market are Boston Scientific Corporation, Medtronic plc, Abbott Laboratories, B. Braun Melsungen AG, Terumo Corporation, Biotronik SE & Co. KG, Biosensors International Group Ltd, Concept Medical Inc., Acotec Scientific AG, Cardionovum GmbH, MedAlliance SA, iVascular SLU, Minvasys SAS, QT Vascular Ltd, Hexacath SAS, Cordis Corporation, MicroPort Scientific Corporation, Endocor GmbH, Orchestra BioMed Inc., Lepu Medical Technology Co. Ltd, Balton Sp. z o.o., BrosMed Medical Co. Ltd

Global Drug-Coated Balloons Market Trends and Insights

Major companies operating in drug-coated balloons are focused on advancing their technologies, such as paclitaxel-coated balloon catheters, to enhance treatment efficacy for conditions like coronary in-stent restenosis, improve patient outcomes, and reduce the risk of complications associated with traditional therapies. Paclitaxel-coated balloon catheters are devices that release the drug paclitaxel into the artery wall when inflated, helping to prevent re-narrowing after angioplasty. For instance, in March 2024, Boston Scientific Corporation, a US-based medical device company, received US Food and Drug Administration (FDA) approval for AGENTTM Drug-Coated Balloon (DCB). This device is intended for the treatment of coronary in-stent restenosis (ISR) in patients with coronary artery disease, which occurs when a stented blood vessel becomes obstructed or narrowed due to plaque or scar tissue.

What Are Latest Mergers And Acquisitions In The Drug-Coated Balloons Market?

In October 2023, Cordis US Corp, a US-based manufacturer of interventional cardiovascular technologies, acquired Med Alliance SA for an undisclosed amount. Through this acquisition, Cordis aims to integrate Med Alliance’s SELUTION SLR sirolimus micro-reservoir drug-coated balloon into its coronary and peripheral portfolios to accelerate market access, expand clinical development, and broaden treatment options for patients with coronary and peripheral vascular disease. Med Alliance SA is a Switzerland-based company that provides drug-coated balloons.

Regional Outlook

North America was the largest region in the global drug-coated balloons market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Drug-Coated Balloons Market?

The drug-coated balloons market consists of sales of everolimus and zotarolimus drug-coated balloons. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.